vs
Side-by-side financial comparison of FGI Industries Ltd. (FGI) and Intellia Therapeutics, Inc. (NTLA). Click either name above to swap in a different company.
FGI Industries Ltd. is the larger business by last-quarter revenue ($30.5M vs $23.0M, roughly 1.3× Intellia Therapeutics, Inc.). FGI Industries Ltd. runs the higher net margin — -8.6% vs -416.2%, a 407.5% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs -14.4%). FGI Industries Ltd. produced more free cash flow last quarter ($2.3M vs $-69.4M). Over the past eight quarters, FGI Industries Ltd.'s revenue compounded faster (-0.5% CAGR vs -10.8%).
FGI Industries Ltd is a global designer, manufacturer and distributor of kitchen and bath products, home organization solutions, and home improvement goods. It serves major retail chains, home specialty stores and e-commerce platforms across North America, Europe and the Asia-Pacific region.
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
FGI vs NTLA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.5M | $23.0M |
| Net Profit | $-2.6M | $-95.8M |
| Gross Margin | 26.7% | — |
| Operating Margin | -2.2% | -428.9% |
| Net Margin | -8.6% | -416.2% |
| Revenue YoY | -14.4% | 78.8% |
| Net Profit YoY | -553.1% | 25.7% |
| EPS (diluted) | $-1.63 | $-0.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.5M | $23.0M | ||
| Q3 25 | $35.8M | $13.8M | ||
| Q2 25 | $31.0M | $14.2M | ||
| Q1 25 | $33.2M | $16.6M | ||
| Q4 24 | $35.6M | $12.9M | ||
| Q3 24 | $36.1M | $9.1M | ||
| Q2 24 | $29.4M | $7.0M | ||
| Q1 24 | $30.8M | $28.9M |
| Q4 25 | $-2.6M | $-95.8M | ||
| Q3 25 | $-1.7M | $-101.3M | ||
| Q2 25 | $-1.2M | $-101.3M | ||
| Q1 25 | $-629.1K | $-114.3M | ||
| Q4 24 | $-402.3K | $-128.9M | ||
| Q3 24 | $-550.1K | $-135.7M | ||
| Q2 24 | $163.6K | $-147.0M | ||
| Q1 24 | $-412.2K | $-107.4M |
| Q4 25 | 26.7% | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | 28.1% | — | ||
| Q1 25 | 26.8% | — | ||
| Q4 24 | 24.6% | — | ||
| Q3 24 | 25.8% | — | ||
| Q2 24 | 30.5% | — | ||
| Q1 24 | 27.4% | — |
| Q4 25 | -2.2% | -428.9% | ||
| Q3 25 | 1.0% | -808.9% | ||
| Q2 25 | -2.7% | -772.2% | ||
| Q1 25 | -3.9% | -726.6% | ||
| Q4 24 | -3.5% | -1059.9% | ||
| Q3 24 | -0.2% | -1589.0% | ||
| Q2 24 | -1.5% | -1998.6% | ||
| Q1 24 | -1.0% | -394.0% |
| Q4 25 | -8.6% | -416.2% | ||
| Q3 25 | -4.6% | -735.2% | ||
| Q2 25 | -4.0% | -710.8% | ||
| Q1 25 | -1.9% | -687.6% | ||
| Q4 24 | -1.1% | -1001.2% | ||
| Q3 24 | -1.5% | -1489.5% | ||
| Q2 24 | 0.6% | -2112.6% | ||
| Q1 24 | -1.3% | -371.3% |
| Q4 25 | $-1.63 | $-0.81 | ||
| Q3 25 | $-0.86 | $-0.92 | ||
| Q2 25 | $-0.64 | $-0.98 | ||
| Q1 25 | $-0.07 | $-1.10 | ||
| Q4 24 | $-0.38 | $-1.27 | ||
| Q3 24 | $-0.29 | $-1.34 | ||
| Q2 24 | $0.08 | $-1.52 | ||
| Q1 24 | $-0.04 | $-1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9M | $449.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.3M | $671.4M |
| Total Assets | $69.5M | $842.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9M | $449.9M | ||
| Q3 25 | $1.9M | $511.0M | ||
| Q2 25 | $2.5M | $459.7M | ||
| Q1 25 | $1.2M | $503.7M | ||
| Q4 24 | $4.6M | $601.5M | ||
| Q3 24 | $3.0M | $658.1M | ||
| Q2 24 | $1.3M | $691.1M | ||
| Q1 24 | $3.3M | $791.3M |
| Q4 25 | $17.3M | $671.4M | ||
| Q3 25 | $19.7M | $748.4M | ||
| Q2 25 | $21.3M | $715.3M | ||
| Q1 25 | $21.8M | $779.9M | ||
| Q4 24 | $22.3M | $872.0M | ||
| Q3 24 | $23.5M | $962.6M | ||
| Q2 24 | $23.8M | $971.1M | ||
| Q1 24 | $23.9M | $1.0B |
| Q4 25 | $69.5M | $842.1M | ||
| Q3 25 | $73.0M | $925.3M | ||
| Q2 25 | $71.7M | $898.9M | ||
| Q1 25 | $68.5M | $986.2M | ||
| Q4 24 | $75.5M | $1.2B | ||
| Q3 24 | $74.7M | $1.2B | ||
| Q2 24 | $69.9M | $1.2B | ||
| Q1 24 | $68.6M | $1.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.3M | $-69.3M |
| Free Cash FlowOCF − Capex | $2.3M | $-69.4M |
| FCF MarginFCF / Revenue | 7.5% | -301.6% |
| Capex IntensityCapex / Revenue | 0.2% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-212.5K | $-395.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.3M | $-69.3M | ||
| Q3 25 | $-1.9M | $-76.9M | ||
| Q2 25 | $7.6M | $-99.6M | ||
| Q1 25 | $-7.4M | $-148.9M | ||
| Q4 24 | $617.4K | $-85.2M | ||
| Q3 24 | $-915.0K | $-84.8M | ||
| Q2 24 | $862.1K | $-58.2M | ||
| Q1 24 | $-8.0M | $-120.7M |
| Q4 25 | $2.3M | $-69.4M | ||
| Q3 25 | $-2.1M | $-76.9M | ||
| Q2 25 | $7.4M | $-99.9M | ||
| Q1 25 | $-7.7M | $-149.7M | ||
| Q4 24 | $-214.1K | $-86.2M | ||
| Q3 24 | $-1.1M | $-86.1M | ||
| Q2 24 | $281.5K | $-59.2M | ||
| Q1 24 | $-8.6M | $-123.2M |
| Q4 25 | 7.5% | -301.6% | ||
| Q3 25 | -5.9% | -558.2% | ||
| Q2 25 | 23.8% | -701.0% | ||
| Q1 25 | -23.3% | -900.1% | ||
| Q4 24 | -0.6% | -669.4% | ||
| Q3 24 | -3.0% | -945.2% | ||
| Q2 24 | 1.0% | -850.9% | ||
| Q1 24 | -28.0% | -425.7% |
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.7% | 0.2% | ||
| Q2 25 | 0.7% | 1.7% | ||
| Q1 25 | 1.1% | 4.4% | ||
| Q4 24 | 2.3% | 7.6% | ||
| Q3 24 | 0.5% | 14.0% | ||
| Q2 24 | 2.0% | 14.5% | ||
| Q1 24 | 2.0% | 8.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 5.27× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FGI
| Sanitaryware | $19.1M | 63% |
| Shower System | $5.8M | 19% |
| Kitchen And Bath Other | $3.3M | 11% |
| Bath Furniture Products | $2.3M | 7% |
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
